A biotech company integrating of AI and synthetic biology to design safer and more effective antibody therapeutics.

Adding to the list of pharma majors starting or expanding production in the USA, Swiss pharma giant Roche (ROG: SIX) today announced that it will invest $50 billion into America in the next five years ...

Japan’s Ono Pharmaceutical and privately-held US firm Jorna Therapeutics are ready to go in a research collaboration ...

South Korea-based biotech firms 1ST Biotherapeutics and LigaChem Biosciences (Kosdaq: 141080) have entered a strategic partnership to co-develop next-generation antibody-drug conjugates and small ...

Galapagos (Euronext: GLPG) has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a ...

Zymeworks (Nasdaq: ZYME), a clinical-stage biotech developing antibody-based therapies for cancer and immune diseases, has ...

Physician attitudes toward patient choice between the use of biologics and biosimilars vary widely across global markets, ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

Russian public procurements of drugs based on the active ingredient semaglutide, which is an original drug from Denmark’s ...

On the research front last week, China-based biotech Remegen released positive Phase III results for its telitacicept in ...

The US subsidiary of Chinese biotech VelaVigo Cayman Limited has announced its second out-licensing agreement of a ...

The National Board of Health and Welfare will pay 80 million kronor ($8.3 million) to the national initiative Genomic ...